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Abstract Telemedicine in chronic diseases like heart
failure is rapidly evolving and has two important goals:
improving and individualising care as well as reducing
costs. In this paper, we provide a critical and an up-
dated review of the current evidence by discussing the
most important trials, meta-analyses and systematic
reviews. So far, evidence for the CardioMEMS device
is most convincing. Other trials regarding invasive
and non-invasive telemonitoring and telephone sup-
port show divergent results, but several meta-analy-
ses and systematic reviews uniformly reported a ben-
eficial effect. Voice-over systems and ECG monitor-
ing had neutral results. Lack of direct comparison
between different modalities makes it impossible to
determine the most effective method. Dutch studies
showed predominantly non-significant results, mainly
due to underpowered studies or because of a high
standard of usual care. There are no conclusive re-
sults on cost-effectiveness of telemedicine because of
the above shortcomings. The adherence of elderly pa-
tients was good in the trials, being essential for the
compliance of telemedicine in the entire heart failure
population. In the future perspective, telemedicine
should be better standardised and evolve to be more
than an addition to standard care to improve care and
reduce costs.
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Key message
– Telemedicine in heart failure is rapidly evolving.
– Evidence is conflicting, mainly due to a lack of
uniform methods/systems.
– Direct comparison between different modalities
is lacking which impedes determination of the
most effective method.
– Telemedicine should evolve into more than an
addition to standard of care.
Background
Heart failure (HF) is an increasingly prevalent disease,
which affects approximately 1–2% of the total pop-
ulation in Europe, despite a tendency towards lower
incidence in recent years [1, 2]. The high prevalence is
mainly due to the ageing population as the prevalence
of HF exponentially increases with age. Not surpris-
ingly, the complexity of the disease is increasing, as
well, and the majority of patients with HF suffer from
multiple comorbidities [1]. Therefore HF is charac-
terised by highmorbidity andmortality, and prognosis
improved only slightly despite advances in treatment
[3]. The high event rate, particularly repeated hospi-
talisations, is the main driver of the enormous costs
and a substantial reduction in quality of life. In order
to prevent these events and to reduce the burden of
HF, a multidisciplinary team approach has been advo-
cated [2]. Multiple meta-analyses demonstrated that
such an approach indeed reduces the burden of HF
[4]. Multidisciplinary treatment not only encompasses
optimal therapy of HF, but also involves patient edu-
cation to improve compliance and self-monitoring by
patients. However, such an approach is quite labour
intensive, requires many resources and monitoring by
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patients is often insufficient. Therefore, telemedicine
has been suggested to support patients at a distance
regarding both education and monitoring and to im-
prove HF care. The implementation of these monitor-
ing tools has been hypothesised to augment medical
control of HF to prevent decompensation, to concur-
rently gain time and resources when compared with
traditional care [5] and to maintain a good standard
of care in the treatment of HF patients despite the
increasing prevalence.
Telemedicine or telehealth are multiform terms
embracing the applications of telematics to medicine
to enable diagnosis, monitoring and/or treatment
remotely by a variety of communication tools, which
may include (smart)phones, mobile wireless devices,
with or without a video connection, or implantable
devices (that are often part of another device such
as ICDs or pacemakers [6]). Until recently, digital
applications in medicine were restricted to the use of
electronic health records, but lately the technological
context has notably expanded: the number of exist-
ing internet-connected mobile devices has roughly
doubled every 5 years [5, 7].
Technology is rapidly evolving. There are a count-
less number of apps available related to healthcare.
New sensors have been developed and data exchange
in real-time enables collection of large datasets. Al-
though many issues are not yet resolved (e.g. data
safety), expectations are high and there are already
healthcare insurers providing reduction in premiums
if e-Health technology is used for prevention or man-
agement of diseases. However, the question arises
what the exact impact is of this technology on the care
in HF, whether it improves quality of life and reduces




So far, the most convincing evidence for a telemoni-
toring device relates to the implantable CardioMEMS
device (Fig. 1; [8]). This device is implanted into the
pulmonary artery (PA) and transmits PA pressures to
a central service centre. The treating physician re-
ceives the results, including the trends over time of
these measurements. The physician is advised to re-
act if PA pressure exceeds a certain threshold which
suggests congestion, and when it is below the nor-
mal range suggesting dehydration. The study was not
powered for mortality but showed significant reduc-
tion in HF hospitalisation as a result of improved HF
management. This effect was maintained in the long
term [9]. A comparable rationale was studied in the
COMPASS-HF trial. A sensor on a transvenous lead
was positioned in the right ventricle (Fig. 2). The pri-
mary endpoint rate was reduced by 21%, but this was
not statistically significant. There were lower event
rates than expected which could make the study un-
derpowered for the primary endpoint [10]. The major
limitation of these studies was that the treatment rec-
ommendation is very generic, with a plethora of in-
terventions being used (diuretics, vasodilators), at the
discretion of the caring physician.
Another form of telemonitoring is part of ICD/CRT
devices. Such monitoring has not generated uniform
results. The IN-TIME trial reported improved clini-
cal outcomes by using multi-parameter monitoring
based on information from an ICD device. By a daily
check of several parameters summarised in Tab. 1,
a composite clinical score indicating worsening of
HF was improved by 37% (odds ratio= 0.63, 95% CI
0.43–0.90) as compared with usual care [11]. The
EFFECT study showed a similar effect with a clear
reduction of the combined primary endpoint of all-
cause mortality and cardiovascular hospitalisation
[12]. Encouraging results were also found in the
COMMIT-HF trial, a matched cohort study, using
different cardiac device brands for the telemonitor-
ing. They observed a long-term effect of significant
reduction in mortality (4.9% vs. 22.3%, p< 0.0001),
but obviously, this was not a randomised trial [13].
In contrast, The OptiLink HF study could not show
any beneficial clinical outcome in advanced HF by
using fluid status telemedicine alerts (Fig. 2; [14]).
Likewise, the positive effects on mortality and cardiac
hospitalisation were not supported in a meta-anal-
ysis including 11 RCTs consisting of 5,703 patients;
there was only a favourable effect on the number of
visits, but no effects on hard clinical outcomes and
an increase in unscheduled visits [15]. As to whether
the differences can be explained by the use of dif-
ferent devices or different interventions is currently
unknown. Therefore, no general recommendation to
use monitoring information from implantable devices
can at present be made.
Non-invasive monitoring
In general, individual trials of telemonitoring/tele-
phone support compared with usual care did not
consistently report positive results on the primary
endpoints (Tab. 1). The large TELE-HF study did
not generate any clinical proof for the use of tele-
monitoring (utilising a telephone-based interactive
voice response system collecting daily information on
symptoms and weight) [16]. A voice response system
was used without direct contact between healthcare
providers, possibly resulting in the low adherence
of 14% never users and only about half of the pa-
tients using the system more than three times per
week [16]. Unfortunately, there was no post-hoc
analysis to determine if good adherence resulted in
better outcomes. Also, the impact of weight changes
for monitoring may be overestimated as it was not
demonstrated to be effective as a predictive marker of
impending decompensation [17]. This is supported
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Fig. 1 CardioMEMS, implantable haemodynamic monitoring
system. a CardioMEMS sensor or transmitter. b Transcatheter
is implanted into a distal branch of the descending pulmonary
artery. c The patient is instructed to take daily pressure read-
ings from home using the home electronics. d Information
transmitted from the monitoring system to the database is im-
mediately available to the investigators for review. e Trans-
mitted information consists of pressure trend information and
individual pulmonary artery pressure waveforms. With permis-
sion from Elsevier, original figure from Abraham et al. Lancet.
2011;377:658–66
by the negative WISH trial that compared a self-
measurement of patients’ weight or by an electronic
scales with automatic transmission of the results to
the clinic. There was a solid mean of 75% (0–100%)
of patient compliance, but there was no significant
difference in endpoints between the groups or in sub-
groups [18]. Also the MCCD trial showed no benefit
of telemonitoring despite very good adherence of the
participants [19]. Again, the system was mainly based
on data transmission with very little direct contact
with the patients. Further, the TIM-HF group failed to
show a positive effect on the primary endpoint of all-
cause mortality or composite endpoints comparing
usual care with telemonitoring (Fig. 3), but the study
was not sufficiently powered [20]. In addition, the
CHAT trial showed mixed results with positive effects
on the secondary endpoints of all-cause mortality
and all-cause hospitalisation with telecommunica-
tion, but not on the primary endpoint in HF patients
living in rural areas [21]. Very recently, the large
TIM-HF2 study found more days alive outside the
hospital with the use of structured remote patient
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Fig. 2 Examples of invasive monitoring. a OptiVOL of
Medtronic pacemaker/ICD devices. b Results presented for
OptiVol with the thoracic impedance (ohms) measured and
the OptiVol fluid index, resulting from the difference of mea-
sured thoracic impedance and reference thoracic impedance,
with threshold. As the patient’s lungs become congested, in-
trathoracic impedance tends to decrease. Similarly, an in-
crease in intrathoracic impedance may indicate the patient’s
lungs are becoming more dry. c The Chronicle® Implantable
Hemodynamic Monitor. d Results of Right Ventricle (RV) Sys-
tolic Pressure measurements of a sensor on a transvenous
lead positioned in the right ventricle and estimated pulmonary
artery diastolic (ePAD) pressures. With permission, original fig-
ure A/B/C from source: Medtronic Inc. With permission from
Elsevier, original figure D from Bourge et al. Am Coll Cardiol.
2008;51:1073–9
management interventions as compared with usual
care (Tab. 1; [22]). Taken together, the inhomogeneity
of the methods used, the devices applied, the patients
included and the intervention performed together
with the lack of sufficient statistical power may ex-
plain the mixed findings of individual trials regarding
the use of telemonitoring. Moreover, there is a lack
of direct comparison between different modalities,
making it impossible to determine which may be the
most effective method.
However, several recent meta-analyses and system-
atic reviews reported that the use of telemonitoring
may improve outcomes [23–26]. As a consequence of
the mixed trials, these meta-analyses included studies
with different inclusion criteria. Despite these differ-
ences, all meta-analyses reported reduction inmortal-
ity and HF-related hospital admissions. In addition,
Kruse et al. concluded that telemedicine is effective in
customer satisfaction [25] and may increase the sense
of security [27]. Also, some but not all studies re-
ported positive effects on quality of life [9, 19, 28].
Still, as many randomised trials were neutral, the rec-
ommendation by the ESC HF guidelines is restrictive
(i. e. recommendation IIB, level B) [2].
Dutch studies
In addition to research design, organisation of health-
care may importantly influence outcomes of health-
care interventions as telemonitoring. By comparing
only Dutch studies, we attempt to create a certain
level of similarity, as organisation of care is com-
parable in all parts of the Netherlands. The first
randomised study including a significant number of
Dutch patients was the TEN-HMS study [29], which
compared telemonitoring with more traditional HF
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Fig. 3 Telemonitoring system for remote monitoring of ar-
rhythmia and heart failure patients. Multi-parameter data
acquisition and transmission should be fully automatic with
smooth data flow to medical staff/arrhythmia and heart failure
monitoring centre. Optimised data workflow: normal data are
automatically stored in a patient’s electronic file without further
detailed evaluation. Alarm threshold crossing triggers detailed
data review and potential medical action. With permission
from Oxford University Press, original figure from Varma N,
Ricci RP. Eur Heart J. 2013;34:1885–95 and reprinted/adapted
figure in Hindricks G, Varma N. Eur Heart J. 2016;37:3164–6
care as nursing telephone support and usual care.
Telemedicine did not differ from nursing telephone
support except for prescription of medication, how-
ever both had significantly better results compared
with usual care for all endpoints (Tab. 2). The Dutch
TEHAF study [30] compared the results of using the
Health Buddy®, monitoring signs and symptoms, with
usual care. HF hospitalisations and visits to the HF
clinic decreased, but the primary endpoint of time
to first HF hospitalisation was not significantly im-
proved. The IN-TOUCH study compared an ICT-
guided disease management support and an ICT-
guided support with additional telemedicine [31].
No significant differences in outcome were found,
possibly due to the lack of a usual care group. The
e-Vita study, a prospective three-arm study (usual
care; usual care plus the heartfailurematters.org web-
site; these two plus an adjusted care pathway with
an interactive platform for disease management (e-
Vita platform), replacing routine outpatient consulta-
tions with HF nurses), could not show any significant
benefit [32]. Lastly, an optimised care program using
a telehealth application in a pre-post design [33] dur-
ing a 12-month follow-up found positive effects on
most outcomes. Due to the design and the limited
study population, the results should be interpreted
with caution.
Taken together, the Dutch studies follow the line of
the overall evidence with mixed results, explained by
the low power of the studies. Endpoints mostly focus
on mortality and care consumption, yet they were not
powered to detect differences. Possibly, the high stan-
dard of usual care may have influenced the results.
The challenge is to detect the important aspects of
the systems and how to integrate the systems into the
daily care process.
Cost-effectiveness
There is limited evidence regarding cost-effectiveness
of telemedicine. The reduction of hospitalisation and
the increased self-management of patients embodies
the potential of cost reduction in healthcare [25]. The
incremental cost-effectiveness of the CardioMEMS
device is estimated to be $ 13,979 per quality-ad-
justed life year gained [8]. Klersy et al. describe in
their meta-analysis on telemonitoring by cardiac de-
vices a reduction of 44% in hospital visits, without
affecting mortality, resulting 15–50% cost saving [15].
In the long term, these interventions were calculated
to be cost-neutral [34].
Regarding non-invasive telemonitoring, the effects
on costs are even less clear. Blum et al. showed no
cost-reduction [19] as there was no positive effect in
the study (e.g. readmission/hospitalisation). In con-
trast, Comín-Colet et al. found a significant reduction
in HF and cardiovascular readmission with the use of
telemedicine, which resulted in a net decrease in di-
rect hospital costs of  3,546 per patient per 6 months
of follow-up [35]. In the Dutch TEHAF study, the prob-
ability of being cost-effective was only 48% (threshold
of  50,000), possibly due to the divergence between
participating institutions [36]. Because of the hetero-
geneity of all the studies, populations and no uniform
intervention it is difficult to be conclusive on cost-
effectiveness.
Potential shortcomings and limitations
One of the shortcomings of telemedicine may be that
patients need to be able to use modern technology.
This may particularly apply to elderly patients, who
usually have less exposure to ICT and may, therefore,
Telemedicine in heart failure—more than nice to have? 11
Review Article
Table 2 Summaries of different Dutch telemedicine studies
Study Design N FU in
months
Intervention Primary endpoint Outcome
TEN-HMS study
(2005)
RCT 426 14–15 TM: TM vs. NTS: negative
3 arms: electronic monitoring of weight;
blood pressure; single lead ECG
days lost because of death
or hospitalisation
(difference –4 days; CI
–15–6)UC; TM; NTS
NTS: (nursing telephone support) TM, NTS vs. UC: positive




TEHAF (2010) RCT 382 12 Health Buddy: Time to first hospitalisation negative
2 arms: Monitoring signs & symptoms;
Education; Support of self-care










and change in health-related
quality of life
negative







electronic monitoring of weight;
blood pressure; ECG (used in
case of start-up or up-titration of
beta-blockers)
e-Vita (2018) RCT 450 12 heart Failure Matters website self-care negative
3 arms: care pathway on e-vita platform HFM vs. UC mean 72.1
vs. 72.7, and EACP vs.
UC 76.1 vs. 72.7,
respectively (overall
p= 0.184)
UC; UC+ HFM web-
site; care path-




pre-post design 102 12 Motiva telehealth system:
providing educational material,
reminders of medication and
motivational messages
no. of HF-hospitalisations positive
(rate ratio 4.1; 95%
CI 2.8–6.3; p< 0.001)
N number of participants, FU follow-up, RCT randomised controlled trial, TM telemonitoring, UC usual care, NTS nursing telephone support, MTS medical
telephone support, CIED cardiac implantable endovascular device, HF heart failure, TM telemonitoring. OR odds ratio, HR hazard ratio, CI confidence interval,
PA pulmonary artery, HF heart failure, CV cardiovascular´, QoL quality of life
either be unable or unwilling to use this technology
[37]. Still, a recent meta-analysis shows that patients
with a mean age of 70 years or more can quickly adopt
telehealth, find its use an acceptable part of their
healthcare routine and are able to maintain good ad-
herence for at least 12 months with a beneficial effect
in reducing the risk of all-cause mortality and HF-re-
lated hospitalisations [38]. The same result is shown in
a post hoc sub-analysis of a Cochrane analysis [26, 39].
Still, it must be stressed that it is very likely, though not
specifically reported, that patients were selected and
these findings might not be applicable to all patients
with HF. This is in line with a recent finding that par-
ticipants and non-participants of e-Health technology
in HF differed significantly, particularly regarding age
[40]. Nevertheless, these findings are interesting and
promising that technology can developed in a way
that it is easy to use for a large proportion of HF pa-
tients [38].
Another shortcoming is that the influence of re-
imbursement adopted by the insurance companies is
probably significant but not yet tested. It is also un-
clear if the reimbursement strategy results in a more
structured use of telemedicine. Also, the organisation
of care may influence the effects of telemedicine. For
this reason, the CardioMEMS system will only be re-
imbursed in the Netherlands within a prospective ran-
domised study to test if the results of the CHAMPION
trial also apply to the Dutch healthcare system.
Moreover, it may be argued that the effect of
telemedicine may be largest in rural areas where
access to good quality healthcare may be more dif-
ficult. The current data do not clearly support that
notion, but studies did not properly investigate the
impact of remoteness of access to care.
Finally, data safety will be an important issue,
particularly for next generation devices that may in-
clude data from electronic patient records. So far,
telemedicine was used mainly as stand alone, limit-
ing data safety issues but also enhanced functionality.
Therefore, issues of data safety should be addressed
more extensively with further development of (new)
devices.
Future perspectives
There are two main goals of telemedicine in HF: im-
proving care and reducing costs. It is not necessar-
ily required that telemedicine devices must strive to
achieve both, but the present and future requirements
in healthcare will actually favour devices aiming to
do so. It is important to much better define which
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goals are important to improve outcome, as high-
lighted above.
Thus far, theoretical considerations have formed
the basis for developing telemedicine devices. These
included the idea that monitoring patients regard-
ing signs and symptoms, via haemodynamic moni-
toring or as part of implantable devices such as ICDs
(e.g. impedance, heart rate variability, activity levels)
would result in a reduction in acute decompensation.
This assumption is not sufficiently supported, and it
is largely unknown what is required to achieve the
best outcome. Best results were achieved with the
use of invasive haemodynamic monitoring [8, 9], but
this is not applicable to the majority of patients and
confirmation in other healthcare systems than initially
tested is required [41, 42]. In addition, a similar kind of
device use (i. e. ICD/CRT-D devices for remote mon-
itoring) resulted in mixed results [11, 43], which can-
not be easily explained. Importantly, the exact ac-
tion required based on the result of monitoring is left
to the care professionals in charge, which obviously
may vary significantly. Therefore, there is an urgent
need for randomised controlled trials with a clear def-
inition of both monitoring and intervention modali-
ties, as well as collection of comprehensive data from
the clinical use of telemedicine devices. Combining
such data based on different systems may help define
which parts of monitoring and patient education are
most effective. However, there is also a great need to
sufficiently record and analyse the therapeutic inter-
vention done based on telemedicine systems. So far,
there is a lack of such data in sufficiently large patient
populations.
Telemedicine has also been advocated to reduce
costs in HF care [35], mainly related to reduction in
hospitalisation rate. However, there may be also a sig-
nificant improvement in self-management in HF as
well as other chronic diseases [44], possibly result-
ing in reduction of outpatient visits as shown for an-
other chronic disease [45]. Current systems have lim-
ited abilities to foster self-management by patients.
Healthcare in Western countries requires a new inno-
vative approach to address chronic diseases such as
HF to provide sustainability of care and to limit the
excessive costs that may threaten the current system.
Thus, changing the approach to care is important, not
only regarding adoption and smarter use of modern
technology, but also regarding a new vision on both
care and health [46]. Therefore, telemedicine should
be more than an addition to standard of care. Impor-
tantly, chronic diseases usually do not occur in isola-
tion. Most patients with chronic disease have multi-
ple diseases [47]. Future telemedicine devices for HF
should consider comorbidities, not only for safety rea-
sons, but to enable real patient self-management that
may enable some substitution of traditional care.
Conclusions
Telemedicine is evolving fast, but lacks solid evi-
dence on clinical outcomes and cost-effectiveness
in trials, despite positive meta-analysis. The Car-
dioMEMS device showed the most convincing results.
For the future, sufficiently powered trials with clear
definition of both monitoring and intervention are
urgently needed. Telemedicine should evolve to be
more than an addition to standard of care. Only then
will telemedicine be more than nice to have.
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